CADL - Conference and earnings call announcements

NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in November 2026. Key Details: Stifel 2026 Healthcare Conference (New York, NY)Date / Time: Tuesday, November 10, 2026, at 9:20 AM ETWebcast Link: Stifel / Candel Fireside Chat Jefferies Global Healthcare Conference (

NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical and mechanistic findings from its phase 1b clinical trial of linoserpaturev in recurrent glioblastoma, through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 4

NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026. Key Details: Citi's 2026 Biopharma Back to School Conference (New York, NY)Date/Time: Wednesday, September 9, 2026, at 10:00AM ETWebcast Link: Citi / Candel Fireside Chat 2026 Cantor Global Healthc

NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present at Canaccord Genuity’s 46th Annual Growth Conference, taking place August 11-13, 2026, in Boston, MA. Presentation Details: Date: Wednesday, August 12, 2026Time: 12 PM EDTWebcast Link: Canaccord Genuity / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations in the Investors section of Candel’s website at www.candeltx.com. A replay of

NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) --  Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present and participate in one-on-one meetings with investors at upcoming investor conferences. Stifel 2026 Virtual Targeted Oncology Forum Date/ Time: Wednesday, May 20, 2026, at 10 AM ETWebcast Link: Stifel / Candel Presentation 2026 Jefferies Global Healthcare Conference (New York, NY)Date/Time: Wednesday, June 3, 2026, at 5:3

NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at TD Cowen's 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday, March 3, 2026 Time: 11:50 AM - 12:20 PM ET Webcast Link: TD Cowen / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News &

NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Francesca Barone, M.D., Ph.D., Candel's Chief Scientific Officer, will present data and participate in multiple sessions at the 7th Annual Glioblastoma Drug Development Summit, taking place February 17-19, 2026 in Boston, Massachusetts. Dr. Barone will share insights from Candel's HSV-based platform and the linoserpaturev (CAN-3110) program in recurrent high-grade glioma (rHGG) through workshop presentations and panel discu

NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom. Presentation Details: Date: Tuesday, November 18, 2025Time: 8:00-8:25 AM GMT / 4:00-4:25 AM ETWebcast Link: Jefferies / Candel Presentation A webcast of the presentation will be available by selecting Events and Pres

NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present insights from its enLIGHTEN™ Discovery Platform, and additional data from the CAN-2409 (aglatimagene besadenovec) program in non-small cell lung cancer (NSCLC), through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland. Dr. Paul Peter Tak, M.D., Ph.D., FMedSci, will also prese

NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will participate in upcoming investor conferences with associated one-on-one investor meetings. Citi's 2025 Biopharma Back to School Conference (Boston, MA)Date/Time: Wednesday, September 3, 2025, at 9:00 AM ETWebcast Link: Citi / Candel Fireside Chat Cantor Global Healthcare Conference (New York, NY)Date/Time: Thursday, September 4, 2025

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference, being held on August 12-14, 2025 in Boston, MA. Date: Wednesday, August 13, 2025Time: 2:00-2:25PM ESTWebcast Link: Canaccord Genuity / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in

NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that management will present and participate in one-on-one meetings with investors at upcoming investor conferences.                                                  Bank of America Securities 2025 Health Care Conference (Las Vegas, NV)Presenter: Francesca Barone, MD, PhD, Candel's Chief Scientific OfficerDate/Time: Wednesday, May 14, 2025, at 4:20 PM PT / 7:20 PM ETWebcast Link: Bank of America / Candel Presentation Jefferies G

NEEDHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel's President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference 2024, being held on November 19-21, 2024. Date: Wednesday, November 20, 2024Time: 9:30-9:55AM GMT / 4:30-4:55AM ESTWebcast Link: https://wsw.com/webcast/jeff315/cadl/1810704 A webcast of the presentation will be available by selecting Events and Presentations under the News & Events t

NEEDHAM, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel's President and Chief Executive Officer, will present at the 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024. Time:Available from 7:00 a.m. ET onwardsDate: Monday, September 9, 2024Webcast Link:https://journey.ct.events/view/0a95e944-f5c6-4d01-8df6-39b94be6d951   A webcast of the H.C. Wainwright presentation will be available

NEEDHAM, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel's President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 3:00 p.m. ET. A live webcast of the fireside chat will be available by selecting Events and Presentations under the News & Events tab in the Investors section on candeltx.com. A replay of the webcast will

NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel's President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 5:30 p.m. ET. A live webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candeltx.com. A replay of the webcast will be archived for up to 90 days fo

NEEDHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023, in New York City. Format: Corporate PresentationDate/Time: Monday, September 11, 2023, at 3:00 pm ET A live webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors secti

NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Canaccord Genuity 43rd Annual Growth Conference, taking place August 7-10, 2023, in Boston. Format: Fireside Chat Date/Time: Thursday, August 10, 2023, at 11:30 am ET A live webcast of the session will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candelt

NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will give a corporate presentation at the upcoming Jefferies Healthcare Conference, taking place June 7 – 9, 2023, in New York City. Format: Corporate PresentationDate/Time: Wednesday, June 7, 2023, at 4:00 pm ET A live webcast of the session will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candel.com. A

NEEDHAM, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2023 Healthcare Talks Oncology Day taking place Feb. 8 – 9, 2023, at the St. Regis Hotel in New York City. Details are as follows: Format: Fireside Chat Date/Time: Wednesday, February 8, 2023, at 3:20 p.m. EST A live webcast of the session will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candel.com. A r

NEEDHAM, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a virtual fireside chat at B. Riley Securities' 3rd Annual Oncology Conference. Details are as follows: Format: Virtual Fireside Chat Date/Time: Thursday, January 19, 2023, at 11:30 am EST A live webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candel.com. A replay of the webcast will be archived for up to 90 days

NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November: Credit Suisse 31st Annual Healthcare Conference Format: In-person Fireside ChatDate/Time: Tuesday, November 8, 2022, at 8:35 am PT BMO Biopharma Spotlight Series: Oncology Day Format: Virtual Fireside ChatDate/Time: Wednesday, November 9, 2022, at 10:00 am ET Jefferies London Healthcare Conference Format: In-person Fireside ChatDate/Time: Wednesday, Nove

NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer will participate in two upcoming investor conferences. Citi's 17th Annual BioPharma ConferenceFormat: Investor meetingsDate: Wednesday, September 7Location: Boston, MA H.C. Wainwright 24th Annual Global Investment ConferenceFormat: Webcast company presentationDate: Monday, September 12Time: 7:00 AM Eastern TimeLocation: VirtualWebcast link: Available here A live webcast of the H.C. Wainwright company pr

Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease stabilization that was ongoing at data cutoff in 62.5 percent of the patients who entered the study with progressive disease and were followed for a minimum of 12 weeksPartial response in 15 percent of the patients Evidence of tumor regression in both injected and uninjected lesionsInduction of local and systemic cytotoxic T cell response after experimental treatment with CAN-2409 Candel to host investor event and webcast at 6:30 am CDT on June 4NEEDHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a late clinical stage b

NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at H.C. Wainwright's upcoming Annual Global Investment Conference. Format: Pre-recorded corporate presentationDate/Time: May 24, 2022, on-demand viewing starts at 7:00 am ET To access the webcast recording of the company presentation, please visit the Candel Therapeutics website at https://ir.candeltx.com/news-and-events/events-and-presentations.  About Cande

NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2022, which will be held in person from June 3 – 7, 2022, at the McCormick Place Convention Center in Chicago, Illinois. The presented data will detail clinical outcomes from Candel's phase 2 clinical trial evaluating CAN-2409 and valacyclovir in combination with anti-PD-1 or PD-L1 agents in patients with stage III/IV NSCLC. Presentation details: Abstract

NEEDHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at the following virtual investor conferences in January: H.C. Wainwright BioConnect ConferenceFormat: Pre-recorded corporate presentationDate/Time: January 10, 2022, on-demand viewing starts at 7:00 am ET B. Riley Securities' 2022 Oncology ConferenceFormat: Live corporate presentationDate/Time: January 28, 2022, at 11:30 am ET To access the webcasts or archived recordi

NEEDHAM, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November: Credit Suisse 30th Annual Healthcare ConferenceFormat: Fireside ChatDate/Time: November 8, 2021, at 11:20 am ET BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in OncologyFormat: Panel DiscussionDate/Time: November 8, 2021, at 12:45 pm ET Jefferies London Healthcare ConferenceFormat: Fireside ChatDate/Time: November 17,